{
  "abstract": "We report on the exploratory use of the recombinant herpes zoster vaccine (RZV, Shingrix) to manage recurrent genital Herpes Simples Virus (HSV-2) infection in a male patient in his early 60s, with bi-monthly outbreaks causing substantial psychological and physical burden. Genital herpes was confirmed through HSV-2 detection in genital swabs and previously managed with acyclovir, either episodically (400 mg three times a day for 5 days) or continuously (400 mg two times a day). The medical history showed no immunodeficiency or significant comorbidities. VZV IgG status was not measured as this is not routinely assessed during an HSV review.",
  "authors": [
    {
      "affiliations": [
        "The Riverside Clinic, James Street West, Royal United Hospital, Bath, UK"
      ],
      "name": "Bret Sheldon Palmer"
    },
    {
      "affiliations": [
        "Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK"
      ],
      "name": "Mark Walker"
    },
    {
      "affiliations": [
        "The Fritchie Unit, Charlton Lane, Gloucestershire Royal Hospital, Gloucester, UK"
      ],
      "name": "Andrew DeBurgh-Thomas"
    },
    {
      "affiliations": [
        "School of Education and Science, Francis Close Hall, Swindon Road, University of Gloucestershire School of Education and Humanities, Cheltenham, UK"
      ],
      "name": "Kerry Rees"
    }
  ],
  "title": "Shingrix vaccination for recurrent genital herpes: a real-world clinic experience",
  "uid": "a2c9d5ff-eee2-5904-8b76-ea4a6577a113"
}